Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989325 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL19212517 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL30989302 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL1246014 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3774795 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL30989337 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL30989339 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL21810753 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL21810763 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13685928 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118359546-A | Nitric oxide donor type ambrisentan derivative, and pharmaceutical composition and application thereof | 江苏海洋大学 | 2024-07-19 | — | — | CN | claimed |
| CN-118359595-A | Nitric oxide donor type atrasentan derivative, and pharmaceutical composition and application thereof | 江苏海洋大学 | 2024-07-19 | — | — | CN | claimed |
| EP-1560804-B1 | A PROCESS FOR THE MONONITRATION OF ALKANEDIOLS | DIPHARMA FRANCIS SRL (IT) | 2009-04-29 | — | — | EP | claimed |
| US-7335789-B2 | Process for the mononitration of alkanediols | DIPHARMA S.P.A. (IT) | 2008-02-26 | — | — | US | claimed |
| US-20060128983-A1 | Process for the mononitration of alkanediols | DIPHARMA S.P.A. (IT) | 2006-06-15 | — | — | US | claimed |
| EP-1560804-A1 | A PROCESS FOR THE MONONITRATION OF ALKANEDIOLS | Dipharma S.p.A. (IT) | 2005-08-10 | — | — | EP | claimed |
| WO-2004043898-A1 | A PROCESS FOR THE MONONITRATION OF ALKANEDIOLS | DIPHARMA S.P.A. (IT) | 2004-05-27 | — | — | WO | claimed |
| CN-117229211-B | NO donor type roflumilast derivative, preparation method, composition and application | 武汉科技大学 | 2026-05-12 | — | — | CN | disclosed |
| US-12612356-B2 | Process for nitrate ester formation of an α,ω-alkanediol monoacylate | DSM IP ASSETS B.V. (NL) | 2026-04-28 | — | — | US | disclosed |
| US-12522558-B2 | Process for the acylation of an alpha, omega-alkanediol | DSM IP ASSETS B.V. (CH) | 2026-01-13 | — | — | US | disclosed |
| CN-115443263-B | Process for acylating alpha, omega-alkanediols | 帝斯曼知识产权资产管理有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119613265-A | Method for preparing omega-nitrooxy-1-alkanol | 帝斯曼知识产权资产管理有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-115427389-B | Process for preparing omega-alkanediol mononitrate | 帝斯曼知识产权资产管理有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2006091716-A2 | NITRIC OXIDE ENHANCING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060128983-A1 | Process for the mononitration of alkanediols | DIPHARMA S.P.A. (IT) | 2006-06-15 | — | — | US | disclosed |
| EP-1560804-A1 | A PROCESS FOR THE MONONITRATION OF ALKANEDIOLS | Dipharma S.p.A. (IT) | 2005-08-10 | — | — | EP | disclosed |
| EP-1534278-A2 | NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004043898-A1 | A PROCESS FOR THE MONONITRATION OF ALKANEDIOLS | DIPHARMA S.P.A. (IT) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004012659-A2 | NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-20040024014-A1 | Nitrosated proton pump inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612356-B2 | Process for nitrate ester formation of an α,ω-alkanediol monoacylate | ELOVL3, ELOVL1, PTGES | CA12 1956/4885CA1 2237/4885CA2 1637/4885 |
| US-20040024014-A1 | Nitrosated proton pump inhibitors, compositions and methods of use | NOS1, PTGS1, NOS2 | CA12 3619/4885CA1 2157/4885CA2 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.